Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News UCB and Sanofi-Aventis laud oral Xyzal

UCB and Sanofi-Aventis laud oral Xyzal

19th February 2008

UCB and Sanofi-Aventis have reported that the oral solution of Xyzal (levocetirizine dihydrochloride) offers patients who dislike pills or have problems swallowing a new alternative to treat their allergies.

The companies had entered into a partnership agreement in September 2006 to launch and co-market Xyzal, with both firms boasting a long history in the field of allergy treatments and both claiming to be dedicated to helping meet previously unmet clinical needs in this area.

A new drug application for a 0.5 mg/ml oral solution of Xyzal has this week been approved by the US Food and Drug Administration to treat chronic idiopathic urticaria and relieve the symptoms of outdoor and indoor allergies.

Michael S Blaiss, clinical professor of paediatrics and medicine at the University of Tennessee Health Science Centre, said: “The oral solution of Xyzal provides a welcome alternative for those patients who have difficulty swallowing or who prefer liquid medication.”

He added that both the tablet and oral solution forms of the drug offer patients long-lasting and powerful relief from the symptoms of their allergies.

In 2006, Schering-Plough announced that a study published in the October issue of Drug Safety found that the administration of Aerius/Neoclarityn (desloratadine) results in less chance of drowsiness than treatment with Xyzal.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.